↓ Skip to main content

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis

Overview of attention for article published in Respiratory Research, April 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (78th percentile)
  • Good Attention Score compared to outputs of the same age and source (74th percentile)

Mentioned by

blogs
1 blog

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
Published in
Respiratory Research, April 2013
DOI 10.1186/1465-9921-14-s1-s5
Pubmed ID
Authors

Vincent Cottin

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease, with a median survival time of 2-5 years. The search for effective treatment has involved numerous clinical trials of investigational agents without significant success. However, in 2011, pirfenidone was the first drug to be approved for the treatment of IPF in Europe. Four key clinical trials supported the efficacy and tolerability of pirfenidone. In the two recently published Phase III CAPACITY trials evaluating pirfenidone (studies 004 and 006), patients with mild-to-moderate IPF were treated with pirfenidone or placebo. Study 004 and pooled analysis of primary endpoint data from both studies showed that pirfenidone significantly reduced decline in percent-predicted forced vital capacity (FVC) compared with placebo (p<0.005). Evidence of beneficial effects of pirfenidone treatment was also observed with regard to several secondary endpoints. Pirfenidone was generally well tolerated, with the most common side effects being gastrointestinal and photosensitivity. Data from the RECAP extension phase of the CAPACITY studies, where patients were treated with pirfenidone for up to three years, further support the manageable tolerability profile of pirfenidone. The efficacy data, coupled with long-term safety data, provide further evidence of a clinically-meaningful treatment effect with pirfenidone in patients with IPF.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Argentina 1 2%
Unknown 54 96%

Demographic breakdown

Readers by professional status Count As %
Other 10 18%
Researcher 9 16%
Student > Master 8 14%
Student > Ph. D. Student 7 13%
Student > Doctoral Student 6 11%
Other 12 21%
Unknown 4 7%
Readers by discipline Count As %
Medicine and Dentistry 25 45%
Agricultural and Biological Sciences 10 18%
Chemistry 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Nursing and Health Professions 1 2%
Other 6 11%
Unknown 6 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2013.
All research outputs
#3,189,710
of 14,013,582 outputs
Outputs from Respiratory Research
#363
of 1,715 outputs
Outputs of similar age
#31,637
of 150,170 outputs
Outputs of similar age from Respiratory Research
#6
of 31 outputs
Altmetric has tracked 14,013,582 research outputs across all sources so far. Compared to these this one has done well and is in the 77th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,715 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 150,170 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.